Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN1A | P35498 | 20/20 | 0.63 |
| ▸ | SCN8A | Q9UQD0 | 20/20 | 0.63 |
| ▸ | SCN5A | Q14524 | 19/20 | 0.56 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.43 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31018066 | 1.00 | SCN1A (0.63) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL21783367 | 0.85 | SCN1A (0.54) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL21783507 | 0.82 | SCN1A (0.60) | SCN1ASCN8ASCN5A | |
| SCHEMBL28549639 | 0.81 | SCN1A (0.64) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL29668910 | 0.80 | SCN8A (0.62) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL20238182 | 0.80 | SCN8A (0.62) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL21783466 | 0.78 | SCN1A (1.00) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL31017718 | 0.78 | SCN1A (1.00) | SCN1ASCN8ASCN5ANR1I2SCN1B | |
| SCHEMBL21773265 | 0.78 | CNR2 (0.41) | — | |
| SCHEMBL21955518 | 0.76 | SCN1A (0.68) | SCN1ASCN8ASCN5ANR1I2SCN1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112638879-B | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2024-06-18 | — | — | CN | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. | 2023-05-02 | — | — | US | disclosed |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2022-11-03 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2021-04-20 | — | — | US | disclosed |
| CN-112638879-A | Heteroaryl substituted sulfonamide compounds and their use as therapeutic agents | 泽农医药公司 | 2021-04-09 | — | — | CN | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-05-21 | — | — | US | disclosed |
| WO-2020047323-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11639351-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
| US-20200157089-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
| US-10981905-B2 | Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
| US-20220348570-A1 | HETEROARYL-SUBSTITUTED SULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | SCN1A, SCN2A, SCN2B | SCN1A 1/4885SCN8A 6/4885SCN5A 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.